SEC
SEC Names Woodcock to Head 1,000-Person Enforcement Division
SEC Chairman Paul Atkins taps Gibson Dunn securities partner David Woodcock to lead the 1,000-person Enforcement Division, effective May 4, 2026.
Latest — Page 40
Deals
Gilead Spends $14.77B on Three Deals, Then Hits Pause
Gilead bought Arcellx, Ouro, and Tubulis for $14.77B in under ten weeks. CFO says further big deals are unlikely this year, but the door stays open.
Deals
KreditBee Hits $1.5B Valuation on $280M Round, Joins Unicorn Club
KreditBee joins India's unicorn club as investors bet on the country's underserved lending market.
FDA
Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead
Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.
Deals
Merck Cut Terns Bid by $1B After Leukemia Data Missed
Merck cut its Terns offer from $7.7B to $6.7B after Phase 1 leukemia data disappointed. The rival bidder walked entirely.
Deals
Whoop Closes $575M Series G as Health Tech Q1 Doubles Down on AI
Whoop's $575M Series G tops a Q1 health tech funding wave built on AI clinical workflow bets, with no post-money valuation disclosed yet.
SEC
SEC's FY2025 Enforcement Take Was $2.7B, Not $17.9B
The SEC's FY2025 enforcement haul drops to $2.7B once you strip the Stanford Ponzi and parallel criminal proceeds from the $17.9B headline.
SEC
SEC Paid $50M+ to One Whistleblower for Early Enforcement Tip
The SEC paid one whistleblower $50M+ for an early tip that triggered an enforcement action, implying at least $167M in underlying sanctions.
Deals
Lilly Bets on Orexins, Tirzepatide Playbook Repeats
Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.
FDA
Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose
Novo Nordisk's 7.2 mg Wegovy is now available in the US, tripling the standard 2.4 mg dose in a direct bid to reclaim ground lost to Lilly's Zepbound.
Deals
Digital Health Posts $4B Q1 Record as 12 Deals Take 59%
Digital health hit $4B in Q1 2026, up $1B year-over-year, but 12 mega-deals claimed 59% of all capital as total deal count fell to 110.
FDA
TrumpRx Lists AbbVie's Humira at $950/Month Next to Cheaper Biosimilars
White House added Humira to TrumpRx at $950/month, the same site that already lists cheaper Pfizer and Amgen biosimilars.
FDA
Amgen's Tepezza Just Got Injectable Data. So Did Viridian.
Amgen's subcutaneous Tepezza cleared Phase 3 as Viridian Therapeutics competes in the same thyroid eye disease market. Both are racing to file with FDA.
FDA
FDA Asks Congress for Market Withdrawal Power Over Manufacturing Gaps
FDA's April 3 budget proposal asks Congress for market withdrawal power over postapproval manufacturing gaps and API supplier non-disclosure.
FDA
Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor
Sanofi's lunsekimig cleared asthma and nasal polyp trials but failed its eczema Phase 2, leaving Dupixent without a clear successor as its patent cliff nears.
